medmix veröffentlicht einen Halbjahresbericht und einen Jahresbericht.
In einem Beitrag in der aktuellen Publikation FOKUS "Future of Healthcare", einer Sonderbeilage der Finanz und Wirtschaft, zeigt medmix, wie Fachwissen in den Bereichen Mischen, Dosieren und präzise Applikation auf verschiedene Anwendungen übertragen werden kann und neue Chancen für Innovationen im Gesundheitswesen entstehen.
medmix has secured an "A" rating in CDP's Supplier Engagement Assessment for the second consecutive year
medmix has secured an "A" rating in CDP's Supplier Engagement Assessment for the second consecutive year
medmix has secured an "A" rating in CDP's Supplier Engagement Assessment for the second consecutive year
medmix’ Drug Delivery (“Haselmeier”) to support the development of Xeris Pharmaceuticals’ XP-8121 with D-Flex™ pen injector
Ad hoc announcement pursuant to Art. 53 LR
medmix strengthens profitability and cash flow while advancing growth and efficiency initiatives
medmix introduces FleXa™, a new customizable syringe platform that advances precision and branding for single-component dental materials.
At today’s annual general meeting (AGM) of medmix Ltd., shareholders approved all proposals of the Board of Directors. medmix will pay an ordinary dividend of CHF 0.10 per share.
medmix has been included in the 2026 edition of the “World’s Best Companies in Sustainable Growth”, a global ranking compiled by TIME Magazine in collaboration with data and research firm Statista.
Ad hoc announcement pursuant to Art. 53 LR
Resilient Performance with Strong Profit Gains in Challenging Markets
medmix’ Drug Delivery (“Haselmeier”) showcased the proven innovation behind its PiccoJect™ platform for high-viscosity drugs at the international conferences PDA Universe in Vienna and PODD in Boston.
medmix wins one of the largest new Beauty businesses in company history and strengthens position in key global beauty markets with facility extensions